Pham Quang X sold $34K of CVKD
Pham Quang X (Chairman, CEO and Interim CFO) sold 11,156 shares of Cadrenal Therapeutics, Inc. (CVKD) at an average of $3.04 ($3.00–$3.05) across 2 trades over 2026-06-25 to 2026-06-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The CEO/Chairman/Interim CFO sold shares in two trades at ~$3.00 and ~$3.05, totaling ~$33.9K, under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor insider activity, but this specific disclosure is unlikely to be a standalone catalyst given the 10b5-1 structure and modest dollar value.
What to watch
The article doesn’t state tax/financing needs, diversification intent, or whether other insiders are buying; without those, the signal is ambiguous.
Background
The article is an SEC Form 4 insider transaction disclosure for Cadrenal Therapeutics, Inc. (CVKD).
Ticker impact
SEC Form 4 shows CVKD CEO/Chairman/10% owner Pham Quang X sold 11,156 shares for about $33.9K at ~$3.00–$3.05.
Near-term impact likely muted; any effect would be sentiment-only rather than a new catalyst.
The filing is primary-source and time-stamped, but the transaction is small relative to typical market moves and explicitly tied to a 10b5-1 plan.
Market effects
No sector-wide read-through; this is company-specific insider trading disclosure.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still coincide with management’s view that near-term upside is limited.
Key entities
- issuerCadrenal Therapeutics, Inc.
Subject of the Form 4 insider sale; ticker CVKD.
- insiderPham Quang X
Chairman, CEO, Interim CFO and 10% owner who executed the open-market sale.
